Skip to main navigation Skip to search Skip to main content

Cost-effectiveness model of renal cell carcinoma (RCC) surveillance in hereditary leiomyomatosis and renal cell carcinoma (HLRCC)

  • Alexander J. Thompson
  • , Yousef M Alwan
  • , Vijay A. C. Ramani
  • , D. Gareth Evans
  • , Eamonn R. Maher
  • , Emma R. Woodward
    • University of Manchester
    • Manchester University NHS Foundation Trust
    • St Mary's Hospital, Stannington
    • University College Birmingham
    • Birmingham Women's NHS Foundation Trust

    Research output: Contribution to journal › Article › peer-review

    11   Link opens in a new tab Citations (SciVal)

    Abstract

    PURPOSE: To determine the cost-effectiveness of annual renal imaging surveillance (RIS) in hereditary leiomyomatosis and renal cell cancer (HLRCC). HLRCC is associated with a 21% risk to age 70 years of RCC. Presentations with advanced renal cell cancer (RCC) are associated with poor outcomes whereas RIS detects early-stage RCC; however, evidence for the cost-effectiveness of RIS is lacking.

    METHODS: We developed a decision-analytic model to compare, at different age starting points (11 years, 18 years, 40 years, 60 years), the costs and benefits of lifetime contrast-enhanced renal MRI surveillance (CERMRIS) vs no surveillance in HLRCC. Benefits were measured in life-years gained (LYG), quality-adjusted life years (QALYs) and costs in British Pounds Sterling (GBP). Net monetary benefit (NMB) was calculated using a cost-effectiveness threshold of £20 000/QALY. One-way sensitivity and probabilistic analyses were also performed.

    RESULTS: In the base-case 11-year age cohort, surveillance was cost-effective (Incremental_NMB=£3522 (95% CI -£2747 to £7652); Incremental_LYG=1.25 (95% CI 0.30 to 1.86); Incremental_QALYs=0.29 (95% CI 0.07 to 0.43)] at an additional mean discounted cost of £2185/patient (95% CI £430 to £4144). Surveillance was also cost-effective in other age cohorts and dominated a no surveillance strategy in the 40 year cohort [Incremental_NMB=£12 655 (95% CIs -£709 to £21 134); Incremental_LYG=1.52 (95% CI 0.30 to 2.26); Incremental_QALYs=0.58 (95% CI 0.12 to 0.87) with a cost saving of £965/patient (95% CI -£4202 to £2652).

    CONCLUSION: Annual CERMRI in HLRCC is cost-effective across age groups modelled.

    Original languageEnglish
    Pages (from-to)41-47
    Number of pages7
    JournalJournal of Medical Genetics
    Volume60
    Issue number1
    Early online date4 Feb 2022
    DOIs
    Publication statusPublished - 23 Dec 2022

    Funding

    ERM acknowledges support from the NIHR Cambridge Biomedical Research Centre, ERW from Cancer Research UK (C64726/A30910), and ERW and DGE from the Manchester NIHR Biomedical Research Centre (IS-BRC1215-20007). The University of Cambridge has received salary support (ERM) from the NHS in the East of England through the Clinical Academic Reserve.

    FundersFunder number
    Manchester Biomedical Research CentreIS-BRC1215-20007
    National Institute for Health and Care Research
    Cancer Research UKC64726/A30910

      UN SDGs

      This output contributes to the following UN Sustainable Development Goals (SDGs)

      1. SDG 3 - Good Health and Well-being
        SDG 3 Good Health and Well-being

      Keywords

      • Female
      • Humans
      • Aged
      • Child
      • Carcinoma, Renal Cell/diagnosis
      • Cost-Benefit Analysis
      • Leiomyomatosis/diagnosis
      • Kidney Neoplasms/diagnosis
      • Quality-Adjusted Life Years

      Fingerprint

      Dive into the research topics of 'Cost-effectiveness model of renal cell carcinoma (RCC) surveillance in hereditary leiomyomatosis and renal cell carcinoma (HLRCC)'. Together they form a unique fingerprint.

      Cite this